Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Forecast for the Advanced Melanoma Market Growth in 2025?
The market size for advanced melanoma has seen considerable expansion in the past few years. Its expected progression is from $3.77 billion in 2024 to $4.13 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 9.4%. The growth experienced during the historical period can be credited to several factors including the approval of dacarbazine, the progression of interferon therapy, the introduction of ipilimumab, the uptake of radiation therapy, the development of combination therapies, the endorsement of nivolumab, and the commencement of pembrolizumab.
What Is the Forecast for the Advanced Melanoma Market Size Through 2029?
The size of the advanced melanoma market is anticipated to experience robust growth in the coming years, indeed, it is projected to escalate to $5.90 billion by 2029, with a compound annual growth rate (CAGR) of 9.3%. The projected expansion during this period can be linked to the progression of innovative checkpoint inhibitors, an increase in tailored therapies, advancements in adoptive cell treatment, a rising trend for combination therapies, the appearance of bispecific antibodies, the broadening landscape of oncolytic virotherapy and an intensified concentration on early detection tools. Key trends during this period consist of AI-assisted diagnostic methods, mRNA-crafted cancer vaccinations, crispr-related gene modification, engineering of oncolytic viruses, modern liquid biopsy technologies, wearable medical monitoring gadgets, sophisticated imaging modalities, 3D bioprinting usage in research, tumor environment modeling, and nanotechnology-centric drug delivery systems.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21088&type=smp
What are the Key Market Players in Advanced Melanoma Market and How They’re Evolving?
Major companies operating in the advanced melanoma market are Pfizer Inc., F Hoffmann-La Roche Ltd, Merck & Co. Inc., Bristol-Myers Squibb, AstraZeneca AG, Novartis AG, GlaxoSmithKline Plc, Amgen Inc., BioNTech SE, Regeneron Pharmaceuticals, Genentech Inc., Exelixis Inc., Dynavax Technologies, Replimune Group, Immunocore Holdings plc, Xencor Inc., Agenus Inc., Nektar Therapeutics, Iovance Biotherapeutics, Adaptimmune Therapeutics, Immutep Ltd., Lytix Biopharma
What Are the Primary Growth Drivers in the Advanced Melanoma Market?
The advanced melanoma market is expected to witness growth due to the rise in the number of severe sunburn cases. Intense skin burns, otherwise known as severe sunburns, are typically caused by an excessive amount of exposure to ultraviolet (UV) radiation, producing symptoms like redness, pain, swelling, and in some instances, blistering. The surge in the number of severe sunburn cases can be attributed to extended exposure to ultraviolet (UV) radiation, a lack of appropriate sun protection, increased participation in outdoor activities during peak UV times, and escalating temperatures due to climate change. Severe sunburns, particularly when they occur repeatedly or in younger years, can induce DNA damage in skin cells, paving the way for genetic mutations that lead to melanoma. As an example, Melanoma Focus, a charity established in the UK to aid the melanoma community, reported in May 2024 that 201 hospital admissions in 2022-23 were due to sunburn, which included 89 children and 25 babies under the age of one. Moreover, 66% of UK-based adults between 16-65 years of age recalled getting sunburned during their childhood, and 65% endured severe sunburn that resulted in blisters at least once. For those with light, pale or white complexions, this number increased to 77%. Thus, the growing incidence of severe sunburns is contributing to the expansion of the advanced melanoma market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=21088&type=smp
What Are the Leading Segments in the Global Advanced Melanoma Industry?
The advanced melanoma market covered in this report is segmented –
1) By Therapeutics: Chemotherapy, Biological Therapy, Targeted Therapy, Immune Therapy
2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
3) By End-User: Hospitals, Cancer Research Centres, Academic Institutes, Diagnostic Centers, Ambulatory Surgical Centers, Other End Users
Subsegments:
1) By Chemotherapy: Alkylating Agents, Antimetabolites, Topoisomerase Inhibitors, Other Chemotherapy Drugs
2) By Biological Therapy: Monoclonal Antibodies, Interferons, Interleukins
3) By Targeted Therapy: BRAF Inhibitors, MEK Inhibitors, KIT Inhibitors, Other Targeted Therapies
4) By Immune Therapy: Immune Checkpoint Inhibitors, Cancer Vaccines, Oncolytic Virus Therapy, Adoptive Cell Transfer
What Are the Key Market Trends in the Advanced Melanoma Industry?
Major corporations in the advanced melanoma market are concentrating on creating cutting-edge products like personalised vaccines, with the aim to boost the effectiveness of treatments, triumph over resistance barriers, and offer tailor-made treatment alternatives, which could ultimately result in improved patient well-being and extended lifespan. Customized vaccines for advanced melanoma are a form of cancer treatment that is crafted for a particular patient, taking into account the distinct genetic variations in their tumour. For instance, in April 2023, Merck & Co. Inc. and Moderna Inc., both US-based companies dealing with pharmaceuticals and biotechnology respectively, were awarded the Priority Medicines (PRIME) scheme designation by the European Medicines Agency (EMA). This was for their experimental personalized mRNA cancer vaccine, mRNA-4157/V940, which they proposed to use in conjunction with Merck’s anti-PD-1 therapy, KEYTRUDA (pembrolizumab) for adjuvant treatment in patients who are at high-risk stage III/IV melanoma after comprehensive resection. The bespoke cancer vaccine mRNA-4157/V940 includes a single artificial mRNA that codes for as many as 34 neoantigens, and is formulated and produced in line with the distinct mutational signature of the patient’s tumour.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/advanced-melanoma-global-market-report
What Is the Regional Outlook for the Advanced Melanoma Market?
North America was the largest region in the advanced melanoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the advanced melanoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21088
This Report Delivers Insight On:
1. How big is the advanced melanoma market, and how is it changing globally?
2. Who are the major companies in the advanced melanoma market, and how are they performing?
3. What are the key opportunities and risks in the advanced melanoma market right now?
4. Which products or customer segments are growing the most in the advanced melanoma market?
5. What factors are helping or slowing down the growth of the advanced melanoma market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model